Ursodeoxycholic acid | CAS:128-13-2 | Manufacturer ChemFaces

Ursodeoxycholic acid

ChemFaces products have been cited in many studies from excellent and top scientific journals

Order & Inquiry & Tech Support

Tel: (0086)-27-84237683
Tech: service@chemfaces.com
Order: manager@chemfaces.com
Address: 176, CheCheng Eest Rd., WETDZ, Wuhan, Hubei 430056, PRC

How to Order

Orders via your E-mail:

1. Product number / Name / CAS No.
2. Delivery address
3. Ordering/billing address
4. Contact information
Order: manager@chemfaces.com

Delivery time

Delivery & Payment method

1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

2. We accept: Wire transfer & Credit card & Paypal

Citing Use of our Products

More Impact Factor than five Cite...

* Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.

According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.

Size /Price /Stock	10 mM * 1 mL in DMSO / $10.8 / In-stock
Other Packaging	*Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap

Featured Products

More...

Geraniin

Catalog No: CFN90256
CAS No: 60976-49-0
Price: $100/20mg

Peonidin-3-O-glucoside chloride

Catalog No: CFN92046
CAS No: 6906-39-4
Price: $318/5mg

Syringaresinol

Catalog No: CFN92060
CAS No: 487-35-4
Price: $268/10mg

Rosmarinyl glucoside

Catalog No: CFN95297
CAS No: 910028-78-3
Price: $413/5mg

Ginsenoside Rg5

Catalog No: CFN92643
CAS No: 186763-78-0
Price: $238/20mg

Epimedin A

Catalog No: CFN99939
CAS No: 110623-72-8
Price: $128/20mg

Psoralen

Catalog No: CFN97142
CAS No: 66-97-7
Price: $30/20mg

Rebaudioside B

Catalog No: CFN90470
CAS No: 58543-17-2
Price: $138/20mg

Isovitexin 2''-O-arabinoside

Catalog No: CFN90943
CAS No: 53382-71-1
Price: $318/10mg

Deoxypodophyllotoxin

Catalog No: CFN99888
CAS No: 19186-35-7
Price: $268/10mg

Description:

Ursodeoxycholic acid is a potent inhibitor of apoptosis, it prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation. Ursodeoxycholic acid can ameliorate experimental ileitis counteracting intestinal barrier dysfunction and oxidative stress, it as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.

Targets:

PARP | ROS | P450 (e.g. CYP17)

In vivo:

Gastroenterology. 2003 Apr;124(4):889-93.

Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.[Pubmed: 12671884 ]

Ursodeoxycholic acid (UDCA) has shown effectiveness as a colon cancer chemopreventive agent in preclinical studies. In addition, a recent report suggests that it also may decrease the risk for developing colorectal dysplasia in patients with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC). We sought to evaluate the effect of UDCA on colorectal neoplasia in a group of patients with UC and PSC enrolled in a randomized, placebo-controlled trial.
METHODS AND RESULTS:
From a prior, randomized, placebo-controlled trial of UDCA therapy in PSC at our center, we followed-up patients with concomitant UC to assess the effect of UDCA on the development of colorectal dysplasia and cancer as compared with placebo. Fifty-two subjects were followed-up for a total of 355 person-years. Those originally assigned to receive UDCA had a relative risk of 0.26 for developing colorectal dysplasia or cancer (95% confidence interval, 0.06-0.92; P = 0.034). Many of the patients originally assigned to the placebo group eventually received open-label UDCA. Assigning these patients to the UDCA group from the time they began active therapy did not change the magnitude of the protective effect (relative risk, 0.26; 95% confidence interval, 0.07-0.99; P = 0.049).
CONCLUSIONS:
UDCA significantly decreases the risk for developing colorectal dysplasia or cancer in patients with UC and PSC.

Dig Dis Sci. 2004 Oct;49(10):1569-74.

Ursodeoxycholic acid ameliorates experimental ileitis counteracting intestinal barrier dysfunction and oxidative stress.[Pubmed: 15573906]

The aim of this study was to evaluate the effect of Ursodeoxycholic acid (UDCA) on intestinal permeability (IP) and reactive oxygen species (ROS) generation in indomethacin-induced enteropathy, a well-known experimental model of Crohn's disease.
METHODS AND RESULTS:
Seventy-eight male Wistar rats were randomly assigned to receive indomethacin, indomethacin + UDCA, or vehicles. Indomethacin induced a significant increase in the fraction of urinary excretion of 51Cr-EDTA following oral administration (7.9 +/- 1.3 vs 2.3 +/- 0.2%; P < 0.05) and lucigenin-amplified chemiluminescence in intestinal fragments ex vivo (10.1 +/- 1.9 vs 2.6 +/- 0.4 cpm x 10(3)/mg; P < 0.05) compared to controls. UDCA significantly reversed these effects (P < 0.05), without being incorporated in biliary bile acid composition (HPLC analysis).
CONCLUSIONS:
These findings support a local protective effect of UDCA in experimental ileitis by the modulation of intestinal barrier dysfunction and oxidative stress. In short, they provide insights into mechanisms of action of UDCA in intestinal inflammation and a new perspective on the treatment of Crohn's disease.

Ursodeoxycholic acid Description

Source:	The bile of bear.
Solvent:	Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Storage:	Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C). Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
After receiving:	The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.

Kinase Assay:

Cell Death Differ. 1999 Sep;6(9):842-54.

Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation.[Pubmed: 10510466 ]

The hydrophilic bile salt Ursodeoxycholic acid (UDCA) is a potent inhibitor of apoptosis.
METHODS AND RESULTS:
In this paper, we further characterize the mechanism by which UDCA inhibits apoptosis induced by deoxycholic acid, okadaic acid and transforming growth factor beta1 in primary rat hepatocytes. Our data indicate that coincubation of cells with UDCA and each of the apoptosis-inducing agents was associated with an approximately 80% inhibition of nuclear fragmentation (P<0.001). Moreover, UDCA prevented mitochondrial release of cytochrome c into the cytoplasm by 70 - 75% (P<0.001), thereby, inhibiting subsequent activation of DEVD-specific caspases and cleavage of poly(ADP-ribose) polymerase. Each of the apoptosis-inducing agents decreased mitochondrial transmembrane potential and increased mitochondrial-associated Bax protein levels. Coincubation with UDCA was associated with significant inhibition of these mitochondrial membrane alterations.
CONCLUSIONS:
The results suggest that the mechanism by which UDCA inhibits apoptosis involves an interplay of events in which both depolarization and channel-forming activity of the mitochondrial membrane are inhibited.

Animal Research:

Gastroenterology. 2002 Oct;123(4):1238-51.

Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles.[Pubmed: 12360485]

The effects of Ursodeoxycholic acid (UDCA) in biliary obstruction are unclear. We aimed to determine the effects of UDCA in bile duct-ligated and in Mdr2 knockout (Mdr2(-/-)) mice with biliary strictures.
METHODS AND RESULTS:
Mice fed UDCA (0.5% wt/wt) or a control diet were subjected to common bile duct ligation (CBDL), selective bile duct ligation (SBDL), or sham operation. UDCA was also fed to 2-month-old Mdr2(-/-) mice. Serum biochemistry, liver histology, and mortality rates were investigated. The biliary tract was studied by plastination, India ink injection, and electron microscopy. The effects of UDCA on biliary pressure were determined by cholangiomanometry. UDCA feeding in CBDL mice increased biliary pressure, with subsequent rupture of cholangioles and aggravation of hepatocyte necroses, resulting in significantly increased mortality. UDCA feeding in SBDL mice aggravated liver injury exclusively in the ligated lobe. Mdr2(-/-) mice developed liver lesions resembling sclerosing cholangitis characterized by biliary strictures and dilatations. UDCA induced bile infarcts in these animals.
CONCLUSIONS:
UDCA aggravates bile infarcts and hepatocyte necroses in mice with biliary obstruction via disruption of cholangioles as a result of increased biliary pressure caused by its choleretic action.

Product Name	Ursodeoxycholic acid
Price:	$30 / 20mg
CAS No.:	128-13-2
Catalog No.:	CFN96464
Molecular Formula:	C₂₄H₄₀O₄
Molecular Weight:	392.58 g/mol
Purity:	>=98%
Type of Compound:	Steroids
Physical Desc.:	Powder
Source:	The bile of bear.
Solvent:	Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Download:	COA MSDS
Similar structural:	Comparison (Web) (SDF)
Guestbook:

Size /Price /Stock	10 mM * 100 uL in DMSO / Inquiry / In-stock 10 mM * 1 mL in DMSO / Inquiry / In-stock
Related Libraries	Hepatoprotective Compound Library Anti-apoptotic Compound Library Steroids Compound Library ROS Inhibitor Library PARP Inhibitor Library P450 (e.g. CYP17) Inhibitor Library

	1 mg	5 mg	10 mg	20 mg	25 mg
1 mM	2.5473 mL	12.7363 mL	25.4725 mL	50.945 mL	63.6813 mL
5 mM	0.5095 mL	2.5473 mL	5.0945 mL	10.189 mL	12.7363 mL
10 mM	0.2547 mL	1.2736 mL	2.5473 mL	5.0945 mL	6.3681 mL
50 mM	0.0509 mL	0.2547 mL	0.5095 mL	1.0189 mL	1.2736 mL
100 mM	0.0255 mL	0.1274 mL	0.2547 mL	0.5095 mL	0.6368 mL

CFN91626	Hyocholic acid	547-75-1	408.6	C₂₄H₄₀O₅
CFN99798	Deoxycholic acid	83-44-3	392.57	C₂₄H₄₀O₄
CFN89170	Lithocholic acid	434-13-9	376.58	C₂₄H₄₀O₃
CFN96673	Sodium cholate	361-09-1	430.55	C₂₄H₃₉NaO₅
CFN96947	Glycodeoxycholic acid	360-65-6	449.63	C₂₆H₄₃NO₅
CFN89075	Glycoursodeoxycholic acid	64480-66-6	449.63	C₂₆H₄₃NO₅
CFN96646	Taurocholic acid	81-24-3	515.70	C₂₆H₄₅NO₇S
CFN96645	Tauroursodeoxycholic acid	14605-22-2	499.70	C₂₆H₄₅NO₆S
CFN80241	Sodium taurochenodeoxycholate	6009-98-9	521.68	C₂₆H₄₄NNaO₆S
CFN96464	Ursodeoxycholic acid	128-13-2	392.58	C₂₄H₄₀O₄